Metformin Treatment in Type 2 Diabetes in Pregnancy: An Active Controlled, Parallel-Group, Randomized, Open Label Study in Patients with Type 2 Diabetes in Pregnancy
Table 2
Maternal outcomes in treatment groups ().
Parameters
Metformin alone
Metformin + insulin
Insulin alone
value
(%)
(%)
(%)
Maternal hypertensive complications in pregnancy
Pregnancy induced hypertension
Yes
1 (6.2)
21 (23.3)
36 (36.0)
0.020*
No
15 (93.8)
69 (76.7)
64 (64.0)
Preeclampsia
Yes
4 (25.0)
9 (10.0)
17 (17.0)
0.184
No
12 (75.0)
81 (90.0)
83 (83.0)
Labor outcomes
Normal vaginal delivery
Yes
3 (18.8)
43 (47.8)
18 (18.0)
<0.01*
No
13 (81.2)
47 (52.2)
82 (82.0)
LSCS
Yes
13 (81.2)
47 (52.2)
82 (82.0)
<0.01*
No
3 (18.8)
43 (47.8)
18 (18.0)
Obstetric outcomes
Mean ± SD
valuea
valueb
valuec
Gestational age at enrolment (weeks)
Metformin alone
10.75 ± 5.98
0.876
Metformin + insulin
10.09 ± 4.86
0.601
Insulin alone
9.57 ± 5.20
0.661
Gestational age at delivery (weeks)
Metformin alone
36.19 ± 1.68
0.409
Metformin + insulin
36.86 ± 1.35
0.134
Insulin alone
37.06 ± 1.22
0.465
value calculated by using Chi-square testMann-Whitney test. aComparison between means of metformin alone and metformin + insulin groups. bComparison between means of metformin alone and insulin alone groups. cComparison between means of metformin + insulin and insulin alone groups. *Significant level ≤0.05.
